Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies

Experimental Hematology

Volumn 40, Issue 6, 2012, Pages 431-435

  Chinratanalab, Wichai ^a   Reddy, Nishitha ^a   Greer, John P ^a   Morgan, David ^a   Engelhardt, Brian ^a   Kassim, Adetola ^a   Brandt, Stephen J ^a   Jagasia, Madan ^a   Goodman, Stacey ^a   Savani, Bipin N ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; FOLINIC ACID; METHOTREXATE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; B CELL LYMPHOMA; BONE MARROW BIOPSY; CANCER MORTALITY; CANCER STAGING; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; INFUSION RELATED REACTION; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SURVIVAL RATE;

ADULT; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PATIENT READMISSION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84860841242     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.01.014     Document Type: Article

References (24)

1. Freytes C.O., Lazarus H.M. Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft?. Bone Marrow Transplant 2009, 44:559-569.
2. Hari P., Carreras J., Zhang M.J., et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008, 14:236-245.
3. Barrett A.J., Savani B.N. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006, 20:1661-1672.
4. Blaise D., Farnault L., Faucher C., et al. Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. Exp Hematol 2010, 38:1241-1250.
5. Michallet M., Le Q.H., Mohty M., et al. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Exp Hematol 2008, 36:535-544.
6. Khouri I.F. Reduced-intensity regimens in allogeneic stem-cell transplantation for non-Hodgkin lymphoma and chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2006, 390-397.
7. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111:5530-5536.
8. Khouri I.F., Bassett R., Poindexter N., et al. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer 2011 Mar 31, [Epub ahead of print]. 10.1002/cncr.26091.
9. Tomblyn M.R., Ewell M., Bredeson C., et al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant 2011, 17:1051-1057.
10. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
11. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
12. Tam C.S., Bassett R., Ledesma C., et al. Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009, 113:4144-4152.
13. Pinana J.L., Martino R., Gayoso J., et al. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica 2010, 95:1176-1182.
14. Reddy N., Savani B.N. Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach. Biol Blood Marrow Transplant 2011, 17:1265-1272.
15. Inamoto Y., Flowers M.E. Treatment of chronic graft-versus-host disease in 2011. Curr Opin Hematol 2011, 18:414-420.
16. Crocchiolo R., Castagna L., El-Cheikh J., et al. Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients. Exp Hematol 2011, 39:892-896.
17. Landgren O., Gilbert E.S., Rizzo J.D., et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009, 113:4992-5001.
18. Peric Z., Cahu X., Chevallier P., et al. Features of Epstein-Barr virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation. Leukemia 2011, 25:932-938.
19. Reddy N., Rezvani K., Barrett A.J., Savani B.N. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant 2011, 17:591-597.
20. Savani B.N., Pohlmann P.R., Jagasia M., et al. Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?. Blood 2009, 113:6263-6264.
21. Berinstein N.L., Grillo-Lopez A.J., White C.A., et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998, 9:995-1001.
22. Aue G., Lindorfer M.A., Beum P.V., et al. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica 2010, 95:329-332.
23. Vianna R.M., Mangus R.S., Fridell J.A., et al. Induction immunosuppression with thymoglobulin and rituximab in intestinal and multivisceral transplantation. Transplantation 2008, 85:1290-1293.
24. Tomblyn M., Lazarus H.M. Donor lymphocyte infusions: the long and winding road: how should it be traveled?. Bone Marrow Transplant 2008, 42:569-579.